References
- Belhadj K, Reyes F, Farcet J P, Tilly H, Bastard C, Angonin R, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 4261–4269
- Wu H, Wasik M A, Przybylski G, Finan J, Haynes B, Moore H, et al. Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Clin Pathol 2000; 113: 487–496
- Navarro J T, Ribera J M, Mate J L, Granada I, Junca J, Batlle M, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003; 44: 531–533
- Grigg A P. 2′-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 2001; 42: 797–799
- Aldinucci D, Poletto D, Zagonel V, Rupolo M, Degan M, Nanni P, et al. In vitro and in vivo effects of 2′-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies. Br J Haematol 2000; 110: 188–196
- Chanan-Khan A, Islam T, Alam A, Miller K C, Gibbs J, Barcos M, et al. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2004; 45: 1673–1675
- Ooi J, Iseki T, Adachi D, Yamashita T, Tomonari A, Tojo A, et al. Successful allogeneic bone marrow transplantation for hepatosplenic gammadelta T cell lymphoma. Haematologica 2001; 86: E25
- Thomas D A, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD program in Burkitt's – Type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461–2470
- Grigg A P, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10: 579–590
- van Besien K W, de Lima M, Giralt S A, Moore D F, Jr, Khouri I F, Rondon G, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977–982
- Burt R K, Guitart J, Traynor A, Link C, Rosen S, Pandolfino T, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 2000; 25: 111–113
- Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2005; 23: 2109–2110
- Yang Y, Qi J, Wang M, Sykes M. Donor-derived interferon γ separates graft-versus-leukaemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 2002; 99: 4207–4215
- Duffner U A, Maeda Y, Cooke K R, Reddy P, Ordemann R, Liu C, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004; 172: 7393–7398
- Spiotto M T, Rowley D A, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10: 294–298